Baird raised the firm’s price target on Healthpeak Properties to $26 from $22 and keeps an Outperform rating on the shares. The firm said its post-merger portfolio is skewed towards outpatient medical, a segment experiencing improving fundamentals that is viewed more positively in the private market. Also, the lab segment will likely remain soft, but leasing activity is improving.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOC:
- Healthpeak Properties resumed with an Equal Weight at Wells Fargo
- Healthpeak Properties resumed with an Outperform at RBC Capital
- Healthpeak Properties price target lowered to $22 from $23 at Scotiabank
- Healthpeak Properties resumed with Neutral from Overweight at JPMorgan
- Physicians Realty Trust Acquisition and Financial Restructuring
